The global neoantigen cancer vaccine market was valued at USD 24.4 million in 2022, and it will advance at a mammoth 67.6% compound annual growth rate, to touch USD 1,322.8 million, by 2030.
 |
| To learn more about this report: https://bit.ly/47EUjP7 |
The key factor boosting the advancement of the industry include the mounting incidence of cancer and surging research activities all over the world. Moreover, because of the growing importance of personalized treatments of cancer, pharmaceutical companies are focusing on R&D to meet the existing and possible requirements for neoantigen cancer vaccines.
Based on product type, the personalized category accounted for the largest share, of 70%, in 2022. Developing personalized cancer vaccines need suitable antigen screening in specific patients. The exceptional potential of personalized neoantigens to induce long-lasting tumor-specific memory T-cell populations has resulted in the mounting utilization of such drugs for effective cancer treatment, therefore boosting the advancement of this category.
In 2022, the nucleic acid category, based on type, accounted for the largest neoantigen cancer vaccine market share, of 55%. This can be attributed to the increasing number of drug manufacturers actively involved in producing advanced and effective nucleic acid-based vaccines.
The APAC neoantigen cancer vaccine industry will witness the fastest growth in the coming years. This is primarily credited to the speedy upgradation in targeted immunotherapy, as a result of the surging number of research initiatives in the regional nations, mainly due to the increasing cases of cancer.
With the surging research activities, as well as the increasing prevalence of cancer all over the world, the neoantigen cancer vaccine industry will continue to advance in the years to come.
